samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > innovative facility concepts for biopharmaceutical multipurpose pilot and production plants
PUBLICATIONS
European Biopharmaceutical Review

Innovative Facility Concepts for Biopharmaceutical Multipurpose Pilot and Production Plants

The manufacturing requirements of biologics, raw materials, starting materials, excipients and APIs (secondary metabolite, prokaryat, cell culture, transgenic plants and animals, blood products, vaccines and so on), and the dosage form required (aseptic filling, vials, ampoules, syringes, pulmonary systems, transdermal systems etcetera), strongly influence the design concept for pharmaceutical facilities. The greatest influential factors on the design of such facilities are the purpose of the plant (mono or multipurpose), and the size of the plant (the production of cytokines requires less equipment and equipment that is smaller than bulk or rHSA, for example). The production of clinical trial material also needs a smaller plant than for market supply.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Hermann Allgaier, Managing Director of Operations at LSMW GmbH
Dr Hermann Allgaier is the Managing Director of Operations for LSMW GmbH, a company providing consultancy, design, construction and validation services for the pharmaceutical and biotech industry. His 17 years of experience include upstream and downstream processing, engineering, analytical services and internal compliance. He was Responsible Head and led the worldwide process development of new chemical entities at Boehringer Ingelheim in Germany.

Dr Allgaier has made numerous presentations and has had work published in the
areas of biopharmaceutical development, manufacturing and general compliance. He is a Member of PDA, ISPE and APV, where he heads the biopharmaceutical section. Dr Allgaier studied Biochemistry at the University of Tübingen, where he received the Friedrich Weygand Award for his PhD work in the field of peptide antibiotics.

spacer
Dr Hermann Allgaier
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON named best Contract Research Organisation in latest string of awards and recognitions

ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, is proud to announce it was named the “Best Contract Research Organisation” of 2021 during the 17th Annual Scrip Awards ceremony on 2 December.
More info >>

White Papers

Nasal Drug Delivery with a Focus on Chronic Rhino-Sinusitis

Aptar Pharma

Aptar Pharma have hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement